IRAK1 and chronic myelogenous leukemia, BCR-ABL1 positive: The CML CD34+ cells were subjected to leukemic stem/progenitor cell expansion culture in the presence of imatinib (0.5 μM), increasing concentrations of IRAK1/4 inhibitor or the combination of these for 7 days (Fig. 4a).